NFE2L2 and cancer: Gsk3 can be considered a characteristic member of aging programs because, unlike Nrf2, Gsk3 activity increases with age and in pathologies associated with aging, such as type 2 diabetes mellitus, cancer, and neurodegenerative diseases.